BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

514 related articles for article (PubMed ID: 31286691)

  • 21. Three cachexia phenotypes and the impact of fat-only loss on survival in FOLFIRINOX therapy for pancreatic cancer.
    Kays JK; Shahda S; Stanley M; Bell TM; O'Neill BH; Kohli MD; Couch ME; Koniaris LG; Zimmers TA
    J Cachexia Sarcopenia Muscle; 2018 Aug; 9(4):673-684. PubMed ID: 29978562
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Local and Systemic Cytokine Profiling for Pancreatic Ductal Adenocarcinoma to Study Cancer Cachexia in an Era of Precision Medicine.
    Gerber MH; Underwood PW; Judge SM; Delitto D; Delitto AE; Nosacka RL; DiVita BB; Thomas RM; Permuth JB; Hughes SJ; Wallet SM; Judge AR; Trevino JG
    Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30513792
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Uncovering Tumor-Promoting Roles of Activin A in Pancreatic Ductal Adenocarcinoma.
    Yu SY; Luan Y; Tang S; Abazarikia A; Dong R; Caffrey TC; Hollingsworth MA; Oupicky D; Kim SY
    Adv Sci (Weinh); 2023 Jun; 10(16):e2207010. PubMed ID: 37083240
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oncogene-Induced Senescence Limits the Progression of Pancreatic Neoplasia through Production of Activin A.
    Zhao Y; Wu Z; Chanal M; Guillaumond F; Goehrig D; Bachy S; Principe M; Ziverec A; Flaman JM; Collin G; Tomasini R; Pasternack A; Ritvos O; Vasseur S; Bernard D; Hennino A; Bertolino P
    Cancer Res; 2020 Aug; 80(16):3359-3371. PubMed ID: 32554750
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Muscle and serum metabolomes are dysregulated in colon-26 tumor-bearing mice despite amelioration of cachexia with activin receptor type 2B ligand blockade.
    Lautaoja JH; Lalowski M; Nissinen TA; Hentilä J; Shi Y; Ritvos O; Cheng S; Hulmi JJ
    Am J Physiol Endocrinol Metab; 2019 May; 316(5):E852-E865. PubMed ID: 30860875
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Macrophages potentiate STAT3 signaling in skeletal muscles and regulate pancreatic cancer cachexia.
    Shukla SK; Markov SD; Attri KS; Vernucci E; King RJ; Dasgupta A; Grandgenett PM; Hollingsworth MA; Singh PK; Yu F; Mehla K
    Cancer Lett; 2020 Aug; 484():29-39. PubMed ID: 32344015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pancreatic cancer induces muscle wasting by promoting the release of pancreatic adenocarcinoma upregulated factor.
    Yoo W; Choi H; Son YH; Lee J; Jo S; Jung D; Kim YJ; Koh SS; Yang YR; Kwon ES; Lee KP; Noh KH; Kim KW; Ko Y; Jun E; Kim SC; Kim S
    Exp Mol Med; 2021 Mar; 53(3):432-445. PubMed ID: 33731895
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MyD88 signalling is critical in the development of pancreatic cancer cachexia.
    Zhu X; Burfeind KG; Michaelis KA; Braun TP; Olson B; Pelz KR; Morgan TK; Marks DL
    J Cachexia Sarcopenia Muscle; 2019 Apr; 10(2):378-390. PubMed ID: 30666818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumour-derived leukaemia inhibitory factor is a major driver of cancer cachexia and morbidity in C26 tumour-bearing mice.
    Kandarian SC; Nosacka RL; Delitto AE; Judge AR; Judge SM; Ganey JD; Moreira JD; Jackman RW
    J Cachexia Sarcopenia Muscle; 2018 Dec; 9(6):1109-1120. PubMed ID: 30270531
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circulating myeloid cells invade the central nervous system to mediate cachexia during pancreatic cancer.
    Burfeind KG; Zhu X; Norgard MA; Levasseur PR; Huisman C; Buenafe AC; Olson B; Michaelis KA; Torres ER; Jeng S; McWeeney S; Raber J; Marks DL
    Elife; 2020 May; 9():. PubMed ID: 32391790
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of ovarian tumour causes significant loss of muscle and adipose tissue: a novel mouse model for cancer cachexia study.
    Luan Y; Zhang Y; Yu SY; You M; Xu PC; Chung S; Kurita T; Zhu J; Kim SY
    J Cachexia Sarcopenia Muscle; 2022 Apr; 13(2):1289-1301. PubMed ID: 35044098
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs.
    Barreto R; Waning DL; Gao H; Liu Y; Zimmers TA; Bonetto A
    Oncotarget; 2016 Jul; 7(28):43442-43460. PubMed ID: 27259276
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatic signal transducer and activator of transcription-3 signalling drives early-stage pancreatic cancer cachexia via suppressed ketogenesis.
    Arneson-Wissink PC; Mendez H; Pelz K; Dickie J; Bartlett AQ; Worley BL; Krasnow SM; Eil R; Grossberg AJ
    J Cachexia Sarcopenia Muscle; 2024 Apr; ():. PubMed ID: 38632714
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metallothionein-1G suppresses pancreatic cancer cell stemness by limiting activin A secretion
    Li K; Zhang Z; Mei Y; Yang Q; Qiao S; Ni C; Yao Y; Li X; Li M; Wei D; Fu W; Guo X; Huang X; Yang H
    Theranostics; 2021; 11(7):3196-3212. PubMed ID: 33537082
    [TBL] [Abstract][Full Text] [Related]  

  • 35. JNK signaling contributes to skeletal muscle wasting and protein turnover in pancreatic cancer cachexia.
    Mulder SE; Dasgupta A; King RJ; Abrego J; Attri KS; Murthy D; Shukla SK; Singh PK
    Cancer Lett; 2020 Oct; 491():70-77. PubMed ID: 32735910
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Distinct cachexia profiles in response to human pancreatic tumours in mouse limb and respiratory muscle.
    Nosacka RL; Delitto AE; Delitto D; Patel R; Judge SM; Trevino JG; Judge AR
    J Cachexia Sarcopenia Muscle; 2020 Jun; 11(3):820-837. PubMed ID: 32039571
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Excessive fatty acid oxidation induces muscle atrophy in cancer cachexia.
    Fukawa T; Yan-Jiang BC; Min-Wen JC; Jun-Hao ET; Huang D; Qian CN; Ong P; Li Z; Chen S; Mak SY; Lim WJ; Kanayama HO; Mohan RE; Wang RR; Lai JH; Chua C; Ong HS; Tan KK; Ho YS; Tan IB; Teh BT; Shyh-Chang N
    Nat Med; 2016 Jun; 22(6):666-71. PubMed ID: 27135739
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Valproic acid attenuates skeletal muscle wasting by inhibiting C/EBPβ-regulated atrogin1 expression in cancer cachexia.
    Sun R; Zhang S; Hu W; Lu X; Lou N; Yang Z; Chen S; Zhang X; Yang H
    Am J Physiol Cell Physiol; 2016 Jul; 311(1):C101-15. PubMed ID: 27122162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Compression of morbidity in a progeroid mouse model through the attenuation of myostatin/activin signalling.
    Alyodawi K; Vermeij WP; Omairi S; Kretz O; Hopkinson M; Solagna F; Joch B; Brandt RMC; Barnhoorn S; van Vliet N; Ridwan Y; Essers J; Mitchell R; Morash T; Pasternack A; Ritvos O; Matsakas A; Collins-Hooper H; Huber TB; Hoeijmakers JHJ; Patel K
    J Cachexia Sarcopenia Muscle; 2019 Jun; 10(3):662-686. PubMed ID: 30916493
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Establishment and characterization of a novel murine model of pancreatic cancer cachexia.
    Michaelis KA; Zhu X; Burfeind KG; Krasnow SM; Levasseur PR; Morgan TK; Marks DL
    J Cachexia Sarcopenia Muscle; 2017 Oct; 8(5):824-838. PubMed ID: 28730707
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.